RECHERCHE :   Cancers du sein
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
BMS CA209-7FL: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
cancer du sein ER positif et HER2 négatif
III
CHUV
CHUV-DO-PART-2016: Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment
Cancer du sein, du poumon ou métastases pulmonaires
II
CHUV
DS8201-A-U303: A Phase III, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antobody drug conjugate (ADC), versus treatment of physician’s choice for HER2low, unresectable and/or metastatic breast cancer subjects
Cancer du sein, HER2 faible, inopérable et/ou métastatique
III
CHUV
IMpassion30/WO39391 : A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PDL1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer
Cancer du sein, triple-négatif
III
CHUV
RACIN, A phase I study of the combination of nivolumab associated with low-dose radiation, aspirin/ celecoxib and either ipilimumab or low-dose cyclophosphamide, followed by nivolumab maintenance, in patients with advanced, TIL-negative solid tumors
Tumeurs solides
I
CHUV
SAKK 21/18: Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A multicenter, randomized phase III trial
Visceral metastatic breast cancer
III
CHUV, HUG
SAKK 23/16 / IBCSG 57-18 / ABCSG-53 Tailored AXIllary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial.
High risk node-positive breast cancer
III
CHUV, HUG
SAKK 96/12: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial
Métastases osseuses dans le cancer de la prostate ou du sein
III
CHUV, HUG
SERENITY: Mindfulness-Based Cancer Recovery program for patients living with a gynecological cancer: a pilot randomized controlled study
gynecological cancer
autre
CHUV, HUG
CHUV-DO-0012-SolTIL-2018 - Phase Ib Study To Assess The Feasibility And Safety Of Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes In Advanced Solid Tumors
Tumeurs solides
I
CHUV
AMGEN 20140299 - T-VEC Breast-Colorectal: A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Cancer du sein métastatique triplement négatif ou cancer colorectal avec métastases hépatiques
I
HUG
IBCSG55-17 - TOUCH: Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer
elderly ER/HER2 positive breast cancer
II
HUG